title: Enhanced delivery of bifidobacteria and fecal changes after multiple oral administrations of bifidobacteria-loaded alginate poly-l-lysine microparticles in human volunteers.
abstract: Enhanced delivery of bifidobacteria and fecal changes were compared following multiple oral administrations of protected bifidobacteria-loaded alginate poly-l-lysine microparticles (bap-microparticles) and unprotected bifidobacteria cultures over a period of 1 month to healthy human volunteers as preliminary in vivo studies. When bap-microparticles were orally administered, enhanced delivery of bifidobacteria was achieved. The viability of the bifidobacteria was significantly increased approximately 11.5-30 times (1.06-1.48 log cycles) during the ingestion period when compared with the bifidobacteria culture group (p < 0.05). However, other gut microflora such as bifidobacteria, enterobacteriaceae, lactic acid bacteria, and staphylococci in feces were not significantly different between the two groups. Encapsulated bifidobacteria resulted in more frequent defecation and decreased fecal viscosity.
authors.affiliation: National Research Laboratory for Bioavailability Control, College of Pharmacy, Kangwon National University, Chuncheon, Korea.
authors.forename: Jing-Hao
authors.initials: JH
authors.lastname: Cui
authors.forename: Qing-Ri
authors.initials: QR
authors.lastname: Cao
authors.forename: Beom-Jin
authors.initials: BJ
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000464:Alginates / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001644:Bifidobacterium / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism; D003672:Defecation; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods*; D004755:Enterobacteriaceae / Q000254:growth & development; D005243:Feces / Q000382:microbiology*; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007778:Lactobacillus / Q000254:growth & development; D008297:Male; D050296:Microbial Viability / Q000187:drug effects; D008863:Microspheres; D010316:Particle Size; D011107:Polylysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D013210:Staphylococcus / Q000254:growth & development; D013997:Time Factors
chemical_list: D000464:Alginates; C051546:alginate-polylysine-alginate; D011107:Polylysine